# KPV peptide FAQ: mechanism, dosage, safety, and legal status > KPV peptide FAQ: what it is, what it does, research doses and routes, safety and the absence of human data, and KPV legal status under FDA 503A. Cited answers, plainly written. Direct, cited answers to what readers ask about KPV peptide — identity, mechanism, research dosing, safety, and regulatory status. ## What is KPV peptide? KPV peptide is the C-terminal tripeptide (lysine-proline-valine, residues 11-13) of alpha-MSH that retains the parent hormone's anti-inflammatory activity while lacking its pigmentary action [4]. It is a single research peptide, not a blend, and across cell and animal studies it dampens inflammation chiefly by suppressing NF-kB and MAP-kinase signaling [1]. ## What does KPV peptide do? In research models KPV dampens inflammation mainly by suppressing NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine production [1]. In the gut it is taken up directly into epithelial cells via the PepT1 transporter, which is upregulated in inflamed tissue [1]. Its action is largely independent of melanocortin receptors [2]. ## What is KPV peptide used for? In the literature KPV is studied for intestinal inflammation and colitis, anti-inflammatory signaling, wound healing, and skin protection [1][4]. The deepest body of work is murine colitis, where oral KPV reduced DSS- and TNBS-induced disease [1]. All uses are preclinical and research-only. ## What is KPV peptide good for? Reported research applications center on gut inflammation (murine colitis), broad anti-inflammatory effects across cell types, corneal and cutaneous wound healing, and protection of skin from inflammatory damage [1][4][6]. The strongest data are in colitis [1][2]. Benefits in humans are not established. ## Is KPV peptide safe? There are no published human clinical trials, so human safety is unestablished; the entire safety picture comes from in vitro and animal work [4]. Those studies were not designed to define a clinical toxicity profile. KPV is research-use-only and not approved for human use in any major jurisdiction. ## What are the benefits of KPV peptide? Across preclinical models, reported effects include reduced colonic inflammation, NF-kB and MAPK suppression, accelerated corneal wound closure, and protection of keratinocytes from inflammatory damage [1][2][6]. Benefits in humans are not established because no human clinical trials of KPV have been published [4]. ## Who should not take KPV peptide? KPV is not approved for human use and has no clinical safety data, so the literature does not define human eligibility [4]. It is sold by chemical suppliers for laboratory research use only. Questions of human suitability cannot be answered from the existing preclinical evidence. ## How long does it take KPV peptide to work? Timelines come from animal models, not people. In rabbits, topical KPV produced complete corneal re-epithelialization by 60 hours (8 of 8 corneas versus none of placebo) [6]. There is no human onset data, and timelines are model-specific rather than generalizable. ## Can you take KPV every day? No human dosing schedule is validated. Animal protocols used continuous oral delivery (for example, ~100 uM KPV in drinking water) or multiple daily topical drops [1][6]; these are research conditions, not human regimens. KPV is research-use-only. ## Is KPV peptide worth it? From an evidence standpoint, KPV is a mechanistically interesting preclinical anti-inflammatory peptide with no human trials [4]. Any human value judgment is premature given the research-only status. The science is promising in animals; it has not been tested in people. ## Can you take KPV and BPC-157 together? No controlled study has evaluated a KPV plus BPC-157 combination; the research record contains no data on co-administration, so any combination is unstudied and research-only. The two are distinct molecules with separate literatures, and there is no evidence base for combining them in humans. ## How often do I inject KPV peptide? The KPV literature is dominated by oral, topical, and local delivery rather than injection, and no human injection frequency exists [1][5]. Framing should describe research routes, not human regimens; there is no validated injection schedule for KPV. ## How quickly does KPV peptide work? Onset data are model-specific and preclinical — for example, corneal healing within roughly 60 hours in rabbits [6]. No human time-to-effect is published, so any speed of action in people is unknown. ## How long should I take KPV peptide for? Study durations were short and model-bound — for example, four-day topical dosing in rabbits [6] and continuous-exposure colitis experiments in mice [1]. There is no validated human course length, and KPV is research-use-only [4]. ## What is KPV peptide dosage? Research doses range from about 10 nM in vitro up to low micromolar, roughly 100 uM in mouse drinking water, and 1-10 mg/mL topical drops [1][6]. There is no established human research dose [4]. The range reflects different routes and models. ## What are KPV peptide side effects? No human side-effect profile exists because there are no human trials; animal studies have not defined a clinical toxicity profile [4]. Free KPV is also peptidase-labile with no validated human pharmacokinetics, a gap the formulation research tries to address [5]. KPV is research-use-only. ## What is KPV? KPV is lysine-proline-valine, a linear tripeptide corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH) [4]. It is written H-Lys-Pro-Val-OH, molecular formula C16H30N4O4, molecular weight 342.44 Da. ## What is KPV used for? In research, KPV is used to study anti-inflammatory signaling and gut and epithelial protection, most heavily in murine models of inflammatory bowel disease [1]. Oral KPV reduced colitis severity in those models [1]. These are research applications, not approved therapies. ## How is KPV related to alpha-MSH? KPV is the C-terminal tripeptide fragment (residues 11-13) of alpha-MSH [4]. It preserves the parent hormone's anti-inflammatory effect but, unlike full alpha-MSH, lacks pigmentary action — the reason it is studied as an anti-inflammatory alternative to the whole hormone [4]. ## Is KPV legal? KPV is sold for laboratory research use only and is not an approved drug or dietary supplement in any major jurisdiction [16]. It is not FDA-approved, and it is currently a candidate scheduled for FDA PCAC evaluation rather than a listed or approved compounding ingredient [18]. ## Can you get KPV from a compounding pharmacy? Compounding access is governed by FDA 503A and 503B rules and bulk-substance eligibility [16]. KPV is not on the 503A bulks list and is a scheduled PCAC candidate, so this is an evolving regulatory question rather than a settled approval [18]. See the [KPV legal status](/legal-status) page for the full reading. ## What is the FDA 503A status of KPV? KPV has no FDA approval and does not appear on the 503A bulks list [16]. FDA has scheduled KPV for PCAC evaluation at the July 23-24, 2026 meeting as a substance "being considered for inclusion on the 503A Bulks List" — a scheduled discussion, not a category placement, listing, or approval decision [18]. --- A regulatory-grade reading of the KPV tripeptide record — each finding marked confirmed, preclinical, or no-human-data and cited to source, and the FDA 503A standing read straight from FDA's own pages; no clinic behind the dossier and nothing here prescribed, dispensed, or sold.